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ABSTRACT
Downregulation of tumor suppressor (TS) microRNAs (miRNAs) commonly occurs 
in human cancer, including multiple myeloma (MM). We previously demonstrated 
that miR-29b is a relevant TS miRNA, whose expression in MM cells is inhibited by 
HDAC4-dependent deacetylation. Here, we provide novel insights into epigenetic 
mechanisms suppressing miR-29b in MM. In MM patient-derived plasma cells, we 
found inverse correlation between miR-29b and EZH2 mRNA expression. Both 
siRNAs and pharmacologic inhibitors of EZH2 led to miR-29b upregulation, and this 
effect was ascribed to reduced H3K27-trimethylation (H3K27me3) of miR-29a/b-1 
promoter regions. Induction of miR-29b upon EZH2 inhibition occurred together 
with downregulation of major miR-29b pro-survival targets, such as SP1, MCL-1 
and CDK6. Knock-down of the EZH2-interacting long non-coding RNA MALAT1 also 
reduced H3K27me3 of miR-29a/b-1 promoter, along with induction of miR-29b and 
downregulation of miR-29b targets. Importantly, inhibition of miR-29b by antagomiRs 
dramatically reduced in vitro anti-MM activity of small molecule EZH2-inhibitors, 
indicating that functional miR-29b is crucial for the activity of these compounds. 
Altogether, these results disclose novel epigenetic alterations contributing to the 
suppression of miR-29b molecular network, which can be instrumental for the 
development of rationally designed miRNA-based anti-MM therapeutics.
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INTRODUCTION
Multiple myeloma (MM) is the second most 
common hematological cancer worldwide and is 
characterized by progressive accumulation of tumor 
plasma cells (PC) in the bone marrow (BM), paraprotein 
production, renal failure and bone destruction [1].
Research carried out in the last decade has disclosed 
an unprecedented role of the non-coding genome in 
PC biology, as well as its relevant contribution to cell 
transformation in the context of PC dyscrasias [2–4]. 
Among non-coding RNAs, to date the best characterized 
class is represented by microRNAs (miRNAs), short non-
coding RNAs that post-transcriptionally regulate gene 
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expression by binding to the 3′ UTR of mRNA targets, 
then triggering mRNA and/or protein degradation [2, 5]. 
Notably, miRNAs can regulate several signal transduction 
pathways involved in MM pathogenesis [6, 7]. Depending 
on their mRNA targets, miRNAs can act either as 
oncogenes [8–13] or as tumor suppressor (TS) miRNAs 
[14–16], which finely tune the interaction between MM 
cells and the BM milieu [3, 17]. Among TS miRNAs, 
our group and others demonstrated that miR-29b is a 
relevant anti-cancer miRNA in a wide variety of solid and 
hematologic malignancies [18]. In MM cells, ectopic miR-
29b was shown to downregulate major tumor promoting 
or anti-apoptotic mRNA targets, including CDK6, MCL-1, 
SP1 [14], as well as mRNAs coding for epigenetic 
regulators, such as HDAC4 [19] and DNMT3A/B [20], 
thus triggering cell cycle arrest and apotosis.
The comprehension of cancer-related mechanisms 
involved in downregulation of miR-29b is nowadays 
a matter of intense investigation, in order to rationally 
design new therapeutic tools restoring the expression 
of this relevant TS miRNA. In this regard, it has 
been demonstrated by us and others that genetic and 
epigenetic aberrations drive the silencing of miR-
29b in hematological malignancies, such as MM and 
acute myeloid leukemia (AML) [18]. In the context of 
epigenetic alterations, aberrant deacetylation of miR-
29a/b-1 promoter by histone deacetylases (HDACs), such 
as HDAC1, HDAC3 [21] and HDAC4 [19] represents 
a well-documented mechanism by which tumor cells 
silence miR-29b; consistently, pan HDAC-inhibitors have 
been found to upregulate miR-29b expression in MM [19], 
AML [21] and CLL [22].
Overexpression of methyltransferases in MM can 
drive malignant transformation through the silencing of 
TS genes/non-coding RNAs; in detail, trimethylation 
of histone H3 at lysine 27 (H3K27me3) or lysine 36 
(H3K36me3), catalyzed by the methyltransferases EZH2 
and MMSET respectively, leads to the silencing of 
established tumor suppressor miRNAs [23, 24].
Here, we aimed at identifying novel epigenetic 
mechanisms regulating miR-29b expression. Our results 
underscore, for the first time, the role of the H3K27 
methyltransferase EZH2 in the negative regulation of 
miR-29b in MM.
RESULTS
miR-29b and EZH2 mRNA expression inversely 
correlates in primary MM PCs 
In an attempt to identify novel epigenetic regulators 
contributing to the silencing of TS miR-29b in MM, 
firstly we evaluated the potential correlation between 
miR-29b and the mRNA expression levels of histone 
methyltransferases with an oncogenic role in MM 
[23], such as EZH1, EZH2 and MMSET. To this aim, 
we interrogated proprietary GEP and miRNA datasets 
obtained from 95 MM and 29 PC leukemia patient-derived 
PCs. Interestingly, a statistically significant inverse 
correlation could be observed only between miR-29b and 
EZH2 (Figure 1A–1C), thus prompting us to investigate 
the potential role of EZH2 on miR-29b regulation.
Inhibition of EZH2 promotes miR-29b 
expression and reduces H3K27me3 marks at 
miR-29a/b-1 promoter 
To investigate the effects of EZH2 on miR-29b 
expression, we analyzed miR-29b levels in JJN3 and AMO-
BZB MM cell lines transfected with scrambled siRNAs 
(as control) or two different EZH2-targeting siRNAs. 
QRT-PCR analysis indicated downregulation of EZH2 
mRNA transcript (Figure 2A) and upregulation of miR-
29b (Figure 2B) as early as 24 hours after EZH2 silencing. 
Moreover, treatment of MM cells with EZH2 inhibitors, 
such as the S-adenosyl-homocysteine hydrolase inhibitor 
3-Deazaneplanocin (DZNep), GSK343 or EPZ005687 
[25, 26], reduced H3K27me3 levels and triggered miR-29b 
upregulation in MM cell lines (Figure 2C). 
We previously showed that miR-29b acts as TS 
miRNA in MM by targeting cell cycle regulators and 
anti-apoptotic genes [14]. WB analysis indicated that 
transfection of EZH2-targeting siRNAs in JJN3 and AMO-
BZB cells triggered downregulation of validated miR-29b 
targets, such as SP1, CDK6, and to a lesser extent MCL-1 
(Figure 2D), indicating that EZH2-depletion induced a 
functionally active miR-29b; downregulation of SP1, CDK6 
and MCL-1 was also achieved after treatment of MM cells with 
EZH2 inhibitors (Figure 2E). Conversely, ectopic expression of 
EZH2 in AMO-BZB cells resulted in downregulation of miR-
29b (Figure 2F). Altogether, these results support a negative 
role of EZH2 on miR-29b expression and activity.
EZH2 is a methyltransferase whose oncogenic 
activity relies on promoter H3K27me3 of TS genes and 
miRNAs, which leads to their transcriptional silencing 
[23, 27]. On this basis, we sought to evaluate whether 
EZH2 could bind and affect the H3K27me3 status of 
miR-29a/b-1 promoter. By using an EZH2 antibody, 
we performed a ChiP assay on AMO-BZB cells: results 
indicate a 7-fold enrichment of miR-29a/b-1 promoter 
sequences in EZH2-immunoprecipitates, as compared 
with control IgG-immunoprecipitates (Figure 3A), 
indicating that EZH2 specifically binds to miR-29a/b-1 
promoter regions. To verify whether miR-29b upregulation 
induced by EZH2 silencing could depend on decreased 
promoter-associated H3K27me3, we analyzed H3K27me3 
status of miR-29a/b-1 promoter by Chip. As expected, 
pharmacologic inhibition of EZH2 by DZNep decreased 
H3K27me3 at miR-29a/b-1 promoter (Figure 3B), thus 
suggesting that miR-29b induction occurs by reduced 
H3K27me3 repressive marks.
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Knock-down of the lncRNA MALAT1 induces 
expression of miR-29b in MM cells
Recent reports have shown that the long non 
coding RNA (lncRNA) MALAT1 interacts with 
EZH2 and positively regulates H3K27me3 repressive 
marks on target gene loci; furthermore, inhibition of 
MALAT1 was shown to abrogate or reduce EZH2-
dependent silencing of target genes [28–30]. To 
assess whether modulation of MALAT1 could affect 
miR-29b expression, we used both gain and loss of 
function experimental strategies. Firstly, AMO-BZB 
cells were transduced with lentivirus expressing 
MALAT1, and levels of miR-29b were determined 
by qRT-PCR. Interestingly, MALAT1 overexpression 
resulted in downregulation of miR-29b levels in 
MM cells (Figure 4A). We further analyzed miR-29b 
levels in AMO-BZB cells treated with selective anti-
MALAT1 antisense oligonucleotides (ASOs) [31], that 
trigger selective RNAse-H dependent degradation of 
MALAT1, or with a scrambled control. As expected, 
MALAT1-targeting ASOs strongly downregulated 
MALAT1 expression, while upregulated miR-29b 
(Figure 4B–4C). To understand if the upregulation of 
miR-29b upon MALAT1 inhibition was due to reduced 
H3K27me3 marks at its promoter, we performed ChiP 
assay with an H3K27me3 antibody: reduced H3K27 
trimethylation of miR-29a/b-1 promoter could be 
observed in MALAT1-depleted cells, as compared 
with control (Figure 4D). Similarly to EZH2-targeting 
siRNAs, anti-MALAT1 ASOs reduced protein levels 
of validated miR-29b targets, such as SP1, MCL-1 and 
CDK6 in MM cells (Figure 4E). These results indicate 
that the lncRNA MALAT1 transcriptionally inhibits 
miR-29b expression by modulating the amount of 
H3K27me3 of its promoter.
Figure 1: Inverse correlation between EZH2 and miR-29b in MM patient-derived plasma cells. Correlation of endogenous miR-
29b levels with EZH2 (A), EZH1 (B) and MMSET (C) mRNA levels, determined by high density microarray analysis of mRNA or 
miRNA expression in GSE73454 (for miR-29b) and GSE73452 (for EZH2 mRNA) datasets. Log values of raw data are reported in graph. 
R = regression coefficient.
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Inhibition of miR-29b abrogates in vitro anti-
MM activity of EZH2 inhibitors 
Small molecule EZH2 inhibitors induce cell cycle 
arrest and apoptosis, and have demonstrated relevant 
anti-tumor activity in preclinical models of MM [26]. 
Since our results show upregulation of miR-29b upon 
EZH2 inhibition, we asked whether sensitivity of MM 
cells to EZH2 inhibitors could rely on miR-29b induction. 
AMO-BZB cells were transduced with specific miR-29b 
inhibitors (levels of miR-29b are reported in Figure 5A), 
and then treated with DZNep, EPZ005687 and GSK343. 
Intriguingly, miR-29b antagonism abrogated the inhibitory 
effects of these compounds on cell proliferation (Figure 5B) 
and cell viability (Figure 5C), thus suggesting that miR-29b 
is crucial in mediating EZH2 inhibitors’ activity.
DISCUSSION
Substantial progresses have been made in the 
comprehension of MM pathobiology, which have translated 
into novel therapeutics, such as proteasome inhibitors, 
immunomodulatory drugs and novel monoclonal antibodies, 
with a significant survival advantage for MM patients 
[1]. There is now compelling evidence that, along with 
protein-coding genes, the non-coding genome is aberrantly 
expressed or dysregulated in cancers, including MM 
[23, 32]. Among the different classes of non-coding RNAs, 
miRNAs have been extensively investigated for their 
oncogenic or tumor suppressive role. In the last decade, 
emerging findings have provided a robust framework for 
developing miRNA-based therapeutics against MM and 
other malignancies [3]. In this regard, we have demonstrated 
that miR-29b is a TS miRNA, whose reinforcement by 
synthetic miR-29b oligonucleotides triggers apoptosis both 
in vitro and in vivo in validated preclinical models of human 
MM [14, 20].
Genetic and epigenetic mechanisms may concur 
to downregulate miR-29b in human cancer [18]. Among 
epigenetic abnormalities, we previously demonstrated that 
the class II histone deacetylase HDAC4 exerts a negative 
control on miR-29b, and its silencing increases acetylation 
at miR-29a/b-1 promoter region thus triggering miR-29b 
expression in MM cells [19]. So far, the contribution of 
Figure 2: Inhibitory effect of EZH2 on miR-29b expression. QRT-PCR analysis of EZH2 (A) and miR-29b (B) expression levels in 
AMO-BZB and JJN3 cells, 24 hours after transfection with 100 nM scrambled siRNAs (SCR) or EZH2-targeting siRNAs (siEZH2#1 and 
siEZH2#2). (C) QRT-PCR of miR-29b levels, 24 hours after treatment of JJN3 with 2 μM DZnep, 5 μM GSK343 or 5 μM EPZ005687; 
WB shows the levels of H3K27me3 and total histone H3 in JJN3-treated cells. (D) WB analysis of SP1, CDK6 and MCL-1, 24 hours after 
transfection of JJN3 or AMO-BZB cells with 100 nM scrambled siRNAs (SCR) or EZH2-targeting siRNAs (siEZH2#1 and siEZH2#2); 
GAPDH was used as loading control. (E) WB analysis of SP1, CDK6 and MCL-1, 24 hours after treatment of JJN3 with 2 μM DZnep, 
5 μM GSK343 or 5 μM EPZ005687; GAPDH was used as loading control. (F) QRT-PCR analysis of miR-29b expression in AMO-BZB 
cells, 24 hours after transfection with  2.5 μg of pEZ-M06-EZH2 plasmid (V-EZH2) or of the empty vector (V-CNT). The blot shows levels 
of EZH2 in AMO-BZB cells, 24 hours after transfection. *P < 0.01.
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other MM-related epigenetic modifications to miR-29b 
regulation, such as histone methylation, has not been 
addressed. Noteworthy, we have here demonstrated, for 
the first time at our knowledge, a negative association 
between the H3K27 methyltransferase EZH2 and miR-
29b in MM. 
EZH2 is a histone methyltransferase member of the 
polycomb repressive complex PRC2, which also includes 
EED, SUZ12, RbAp48 and other accessory proteins [23, 
33, 34]. The SET domain of EZH2 represents the catalytic 
subunit which catalyzes the tri-methylation of H3K27, a 
histone post-translational modification associated with the 
repression of gene expression [35]. Importantly, EZH2 
has been largely involved in B-cell pathophysiology, 
as demonstrated by evidence that, in germinal centers, 
high EZH2 levels trigger B cell expansion, while EZH2-
activating mutations may promote development of diffuse 
large B-cell and follicular lymphomas [36, 37]. EZH2 
mRNA expression increases during progression from 
monoclonal gammopathy of undetermined significance 
(MGUS) through smoldering MM to overt MM [38, 39], 
and high EZH2 mRNA expression in newly-diagnosed 
MM patients associates with poor outcomes and high-
risk clinical features [26]. All these findings underscore a 
relevant role of EZH2 in MM pathogenesis. Interestingly, 
EZH2 and its homolog EZH1 are promising targets for 
therapeutic intervention in MM, since small molecule 
inhibitors of EZH1/2 trigger cell cycle arrest and apoptosis 
in MM cell lines and primary CD138+ cells [25, 26, 40], 
and stem cells [41] as consequence of upregulation of 
H3K27me3-silenced genes, including the CDK inhibitors 
CDKN1A/p21 and CDKN2B/p15.
By interrogating GEP and miRNA datasets, we 
found that miR-29b and EZH2 mRNA levels inversely 
correlated. This finding prompted us to investigate 
whether EZH2 might regulate miR-29b. In this regard, 
we here provide formal proof that EZH2 exerts a negative 
control on miR-29b, since its genetic or pharmacological 
inhibition triggers miR-29b upregulation. Mechanistically, 
we here demonstrate that EZH2 binds the miR-29a/b-1 
promoter, and H3K27me3 repressive marks at miR-
29a/b-1 promoter may contribute to miR-29b silencing, 
since reduced H3K27me3 at miR-29a/b-1 promoter 
accompanies miR-29b upregulation upon EZH2 
pharmacological blockade. We also show that EZH2 
inhibition triggers a functionally active miR-29b, as 
demonstrated by downregulation of validated miR-29b 
targets in MM cells transfected with EZH2-targeting 
siRNAs or treated with small molecule EZH2 inhibitors. 
Recent evidence has suggested that the lncRNA 
MALAT1 interacts with members of the PRC2 complex 
and positively modulates the H3K27me3 activity of EZH2. 
LncRNAs represent more than half of the mammalian 
non-coding transcriptome, and are involved in different 
biological processes, such as transcriptional regulation, 
maintenance of genomic integrity, X-chromosome 
inactivation, genomic imprinting, cell differentiation, 
and development [32, 42]. MALAT1 acts as oncogenic 
Figure 3: EZH2 binds miR-29a/b-1 promoter and regulates its H3K27me3. (A) Chip assay using an EZH2 antibody, or IgG isotypic 
control, was performed in AMO-BZB cells. Results are the average of three independent experiments performed in triplicate and show 
enrichment of EZH2 at miR-29a/b-1 promoter regions. *P < 0.01. (B) Chip assay using an H3K27me3 antibody or IgG isotypic control, in 
AMO-BZB cells treated with DMSO or 2 μM DZNep for 24 hours. Results are the average of three independent experiments performed in 
triplicate and show reduction of H3K27 trimethylation at miR-29a/b-1 promoter regions after inhibition of EZH2 with DZNep. *P < 0.01 
respect to DMSO-treated cells.
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lncRNA in a wide variety of solid and hematological 
malignancies, including osteosarcoma [28], renal cell 
carcinoma [29], colorectal [43], prostate cancer [30], 
esophageal carcinoma [44], T, NK [45] and mantle 
cell lymphomas [46]. Recent reports indicate that high 
MALAT1 expression levels predict poor prognosis of 
cancer patients [28, 29] and MALAT1 knock-down blocks 
epithelial to mesenchymal transition and triggers cell 
cycle arrest and apoptosis, associated to reduced binding 
of EZH2 to its target loci and consequent upregulation of 
EZH2-repressed genes [28, 29, 47]. We recently carried 
out the first lncRNA profiling of PC malignancies, which 
identified several lncRNAs deregulated in tumor samples 
compared to normal controls; among these, upregulation 
of MALAT1 was associated with activation of pathways 
involved in cell cycle regulation [48]. In line with its 
acknowledged role as EZH2 positive modulator, silencing 
of MALAT1 by ASOs mimicked the molecular effects 
produced by EZH2 inhibition, as shown by: i) miR-29b 
upregulation, ii) reduced H3K27me3 at miR-29a/b-1 
promoter, and iii) downregulation of miR-29b target genes 
upon MALAT1 inhibition. The effects of MALAT1 and 
EZH2 on miR-29b expression are summarized in Figure 6.
Finally, the findings that miR-29b blockade 
dramatically impairs the anti-MM activity of DZNep, 
GSK343 and EPZ005687 disclose relevant implications for 
the design of targeted therapeutic approaches against MM 
and other malignancies, in which the tumor suppressive 
role of miR-29b is well acknowledged. Given that miR-29b 
seems to be an important effector of the anti-MM activity 
Figure 4: MALAT1 knock-down upregulates miR-29b expression. (A) QRT-PCR analysis of miR-29b and MALAT1 in AMO-BZB 
cells after transduction with an empty vector (V-CNT) or a vector containing MALAT1 cDNA (V-MALAT1). QRT-PCR analysis of 
MALAT1 (B) or miR-29b (C) expression levels, 72 hours after treatment of AMO-BZB cells with 2.5 μM naked MALAT1 ASOs at the 
indicated concentrations. *P < 0.01. (D) Chip assay using an H3K27me3 antibody or IgG isotypic control, 72 hours after treatment of 
AMO-BZB cells with naked MALAT1 ASOs. Results are the average of three independent experiments performed in triplicate and show 
reduction of H3K27 trimethylation at miR-29a/b-1 promoter regions after MALAT1 knock-down with ASOs. *P < 0.01 respect to ASO-
control treated cells. (E) WB analysis of SP1, CDK6 and MCL-1, 72 hours after treatment of AMO-BZB cells with naked MALAT1 ASOs 
or control ASOs. GAPDH was used as loading control.
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of small molecule EZH2 inhibitors, it is reasonable that 
the design of anti-tumor strategies targeting EZH2 should 
take into account the miR-29b status of tumor cells, and 
that upregulation of miR-29b after treatment may be likely 
predictive of response to these drugs.
In conclusion, our findings widen the spectrum of 
epigenetic abnormalities inducing downregulation of miR-
29b in MM, and provide the molecular basis to rationally 
develop tailored epigenetic therapies against this still fatal 
malignancy.
MATERIALS AND METHODS
Cell lines, transfection and reagents
JJN3 MM cell line was purchased from DSMZ and 
cultured in DMEM supplemented with 20% FBS and 1% 
P/S (Gibco®, Life Technologies), while AMO-BZB MM 
cell line was provided by Dr. C. Driessen (University 
of Tubingen, Germany), and cultured in RPMI-1640 
(Gibco®, Life Technologies), supplemented with 10% 
FBS, 1% P/S (Gibco®, Life Technologies), at 37°C in a 
5% CO2 atmosphere. JJN3 and AMO-BZB transfection 
was performed by the Neon® Transfection System (Life 
Technologies) as previously described [49], with the 
following electroporation protocol: 2 pulses, 1050 V, 
30 milliseconds. Silencer® Select siRNA for EZH2 
(siEZH2) and Silencer® Select siRNA control (SCR) 
were purchased from Life Technologies and used at final 
concentration of 100 nM. MALAT1 synthetic inhibitors 
(MALAT1i) LNATM longRNA GapmeRs were purchased 
by Exiqon (Vedbaek, Denmark). MALAT1i sequence was 
ACATTGCCTCTTCATT; a mismatch LNATM longRNA 
GapmeR (named g CNT: GCTCCCTTCAATCCAA) 
was used as negative control. 3-Deazaneplanocin A 
(DZNep) was purchased by Sigma Aldrich and dissolved 
in DMSO; EPZ005687 and GSK343 were purchased from 
Selleckchem and dissolved in DMSO. 
Reverse transcription (RT) and quantitative 
real-time amplification (qRT-PCR) 
Total RNA was extracted from cells using TRIzol® 
reagent (Gibco, Life Technologies, Carlsbad, CA), following 
the manufacturer’s instructions. The RNA quantity and 
quality was assessed through NanoDrop® (ND-1000 
Spectrophotometer). To evaluate gene expression levels, 
1000 ng of total RNA were reverse transcribed to cDNA 
using the “High Capacity cDNA Reverse Transcription 
Kit” (Applied Biosystems, Carlsbad, CA). The single-tube 
TaqMan assays (Applied Biosystems, Carlsbad, CA) were 
used to detect and quantify genes: EZH2 (Hs01016789_m1), 
MALAT1 (Hs00273907_s1) according to the manufacturer’s 
instructions, using Viia 7 Dx multicolor detection system 
(Applied Biosystems, Carlsbad, CA). The obtained 
Threshold Cycle (CT) values were normalized on GAPDH 
(Hs03929097_g1). The single-tube TaqMan miRNA 
assay (Applied Biosystems, Assay id 000413) was used to 
detect and quantify mature miR-29b expression, that was 
normalized on RNU44 (Applied Biosystems, Assay id 
001094). Comparative real-time polymerase chain-reaction 
(RT-PCR) was carried out in triplicate, including no-template 
controls. Relative expression was calculated using the 
comparative cross threshold (Ct) method. 
Expression vectors
pEZ-M06-EZH2 plasmid containing EZH2 
cDNA and the corresponding empty vector were from 
Genecopoeia (GeneCopeia, Rockville, MD, USA). 
MALAT1 cDNA in pCMV-SPORT6 (Dharmacon GE) 
was subcloned by the Genomics facility of Biogem IRGS 
(Ariano Irpino, Italy) using PmeI and BamH1 restriction 
Figure 5: miR-29b antagonism impairs in vitro anti-MM activity of EZH2 inhibitors. (A) QRT-PCR analysis of miR-29b expression 
levels in AMO-BZB transduced with GFP control or miR-29b inhibitors (antimiR-29b). Trypan blue exclusion assay (B) and CTG viability 
assay (C) were performed in AMO-BZB cells stably transduced with GFP control or miR-29b inhibitors (anti-miR-29b), 72 hours after 
treatment with 2 μM DZnep, 5 μM GSK343 or 5 μM EPZ005687. *P < 0.05.
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sites, in a modified pGREENpuro lentiviral vector (System 
Biosciences) where the H1 promoter was replaced with the 
CMV promoter.
Western blotting
SDS-PAGE and Western Blotting (WB) were 
carried out according to standard protocols [50, 51]. 
Briefly, cells were lysed and whole cells lysates 
(~50 μg per lane) were separated using 4–12% Novex 
Bis-Tris SDS-acrylamide gels (Invitrogen) and electro-
transferred on nitrocellulose membranes (Bio-Rad). Then, 
nitrocellulose membranes were blocked with milk and 
probed over-night with primary antibodies at 4°C, then 
membranes were washed 3 times in PBS-Tween, incubated 
with a secondary antibody conjugated with horseradish 
peroxidase for 2 hours at RT. Chemiluminescence was 
detected using Western Blotting Luminol Reagent (Santa 
Cruz, Dallas, TX, USA). Signal intensity was quantified 
with the Quantity One Analyzing System (Bio-Rad). 
Antibodies used were the following: EZH2 (cat#5246S), 
CDK6 (cat#3136S) and MCL1 (cat#5453S) were from 
Cell Signaling, while SP1 (sc-14027), ACTIN (sc-1616) 
and GAPDH (sc-25778) were from Santa Cruz.
Chromatin immunoprecipitation 
For chromatin immunoprecipitation (ChIP) 
experiments, the ChIP Assay Kit (Pierce Agarose ChIP 
Thermo Fisher Scientific) was used. Cells (1.5 × 107) 
were crosslinked in 1% formaldehyde, lysed, and sheared 
by sonication using the Bioruptor Plus (Diagenode), for 
10 cycles (each of 30 seconds) on a cold block, with 90 
seconds intervals of cooling. Chromatin was divided into 
equal amounts for immunoprecipitation with the histone 
H3 (tri-methyl K27) antibody (Abcam, ChIP Grade 
ab6002), EZH2 (Abcam, ChIP Grade ab3748) or rabbit 
IgG as negative control (Santa Cruz Biotechnology). 
Chromatin extracts were incubated on a rotator with 20 μl 
of ChIP Grade Protein A/G Plus Agarose for 3 h at 4°C. 
Bound agarose beads were harvested by centrifugation 
(12.000rpm, 15 seconds) and washed; precipitated protein-
DNA complexes were eluted from the washed beads and 
incubated twice at 65°C for 1.5 h with NaCl and Proteinase 
K to revert cross-links. Purified DNA was subjected to 
qRT-PCR using GoTaq qPCR Master Mix (Promega). 
Primer sequences for qPCR were as follows: miR-29a-b1 
promoter: Fw 5ʹ-3ʹ: CATGCCTGTAGTGAGGCTGA; 
Rev 5ʹ-3ʹ: TCCTGAGTAGCTGG GATTGC.
Virus generation and infection of MM cells
293Ta cells were co-transfected with 10 μg of 
lentiviral expression vector or the corresponding empty 
vector, 10 μg of pCMV-VSVG, and 4 μg of ∆8.9 plasmids 
as previously reported [14]; supernatants were collected 
48 hours after 293Ta transfection, and used to transduce 
MM cells by a single round of 15 hours of infection. MM 
cells were then selected in medium containing 0.5 μg/mL 
puromycin (Sigma Aldrich).
Analysis of cell viability and proliferation
Cell viability and proliferation were analyzed by 
Cell Titer Glo (Promega) and Trypan blue exclusion 
(Sigma Aldrich), respectively, as described [50]. 
Figure 6: Graphic overview of the inhibitory effect played by EZH2 and MALAT1 on miR-29b expression. The cartoon shows that 
MALAT1 and EZH2 negatively regulates miR-29b expression by increasing H3K27me3 of miR-29a/b-1 promoter, thus affecting levels of 
miR-29b oncogenic targets SP1, MCL-1 and CDK6.
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Statistical analysis 
Each experiment was performed at least 3 times, and 
values reported as means +/− SD. Comparisons between 
groups were made with Student t test, while statistical 
significance of differences among multiple groups was 
calculated by GraphPad software (www.graphpad.com). Only 
results with P < 0.05 were accepted as statistically significant.
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